Package 67877-833-61

{"route": ["ORAL"], "spl_id": "775b5984-dab8-42b5-ab48-d1af773b4066", "openfda": {"nui": ["N0000008486", "N0000185506", "N0000182140"], "unii": ["0H73WJJ391"], "rxcui": ["2586427"], "spl_set_id": ["7bc4ec7a-9b83-4842-9057-e1a804b2596d"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "manufacturer_name": ["Ascend Laboratories, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "473 mL in 1 BOTTLE (67877-833-47)", "package_ndc": "67877-833-47", "marketing_start_date": "20250707"}, {"sample": false, "description": "1 BOTTLE in 1 CARTON (67877-833-61)  / 120 mL in 1 BOTTLE", "package_ndc": "67877-833-61", "marketing_start_date": "20250707"}], "brand_name": "TOPIRAMATE", "product_id": "67877-833_775b5984-dab8-42b5-ab48-d1af773b4066", "dosage_form": "SOLUTION", "pharm_class": ["Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "product_ndc": "67877-833", "generic_name": "TOPIRAMATE", "labeler_name": "Ascend Laboratories, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "TOPIRAMATE", "active_ingredients": [{"name": "TOPIRAMATE", "strength": "25 mg/mL"}], "application_number": "ANDA217795", "marketing_category": "ANDA", "marketing_start_date": "20250707", "listing_expiration_date": "20261231"}